Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Aclaris Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +8 vs. Q2 2025
- Shares held
- 85.7M
- −6.18M (−6.7%) vs. Q2 2025
- Total value
- $162.8M
- +$32.4M (+24.8%) vs. Q2 2025
- New holders
- 15
- 26 more added
- Sold out
- 7
- 40 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 148 | $630.0M |
| Q1 2026 | 136 | $409.4M |
| Q4 2025 | 122 | $252.1M |
| Q3 2025 | 103 | $162.8M |
| Q2 2025 | 96 | $130.4M |
| Q1 2025 | 109 | $143.8M |
| Q4 2024 | 98 | $217.0M |
| Q3 2024 | 81 | $58.5M |
| Q2 2024 | 98 | $58.1M |
| Q1 2024 | 98 | $67.5M |
| Q4 2023 | 107 | $61.4M |
| Q3 2023 | 138 | $480.0M |
| Q2 2023 | 133 | $737.2M |
| Q1 2023 | 149 | $579.3M |
| Q4 2022 | 128 | $1.04B |
| Q3 2022 | 127 | $1.00B |
| Q2 2022 | 115 | $883.3M |
| Q1 2022 | 110 | $1.02B |
| Q4 2021 | 133 | $814.9M |
| Q3 2021 | 126 | $1.02B |
| Q2 2021 | 128 | $983.4M |
| Q1 2021 | 97 | $1.14B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Aclaris Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 6,515,458 | $12.4M | 0.00% | −146,605−2.2% | Reduced |
| Vivo Capital, LLC | 8,888,888 | $16.9M | 1.36% | 00.0% | Unchanged |
| BML Capital Management, LLC | 14,250,000 | $27.1M | 24.91% | 00.0% | Unchanged |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −451,120−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −390,583−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −46,969−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1,292−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −902−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,336−100.0% | Sold out |
| CIBC World Markets Corp | – | – | – | – | Not filed |